RHON-KLINIKUM AG closed the first nine months of 2026 with improved earnings and patient numbers, demonstrating resilience amid healthcare policy challenges and a difficult economic environment. The group treated 764,248 patients on an inpatient and outpatient basis, an 8.3% increase from the previous year, while consolidated revenue rose to EUR 1,303.8 million from EUR 1,262.1 million. EBITDA reached EUR 83.9 million, and consolidated profit climbed to EUR 32.7 million, up from EUR 25.1 million in the same period of 2025. The increase was primarily driven by higher capacity utilization at clinics and medical care centers, along with growth in outpatient patient numbers.
The results were further supported by a 3.25% billing surcharge on hospital services, accounted for under "other income" through October 2026, intended to offset prior increases in personnel and non-personnel costs. The company’s strong capital base, reflected in an equity ratio of 74.7%, provides a solid foundation for optimizing inpatient and outpatient care structures. According to Dr. Gunther K. WeiB, member of the Board of Management, “Our successful third quarter shows that financial stability and medical excellence are inseparable, going hand in hand. Underlying this success is the tremendous trust our patients put in us. This sustainable basis is what allows us to continue making targeted investments in state-of-the-art medical technology and care offerings.”
These investments include the installation of a state-of-the-art photon-counting computer tomograph at Universitatsklinikum Marburg, making RHON-KLINIKUM AG the only hospital group in Germany with four newest-generation units in operation. Additionally, a new hybrid operating theatre in Frankfurt (Oder) has expanded the hospital’s treatment range, strengthened interdisciplinary structures, and enhanced care offerings in the Ostbrandenburg region. Dr. Stefan Stranz, also a member of the Board of Management, noted, “This forward-looking investment strategy ensures that we can continue to operate effectively in a market environment facing far-reaching and sweeping change. Thanks to our solid financial basis and our collaboration within the ASKLEPIOS Group network, we can take on and actively shape this transformation process from a position of strength.”
For the full year 2026, RHON-KLINIKUM AG expects revenues of EUR 1.7 billion within a range of plus or minus 5%, and EBITDA between EUR 110 million and EUR 125 million. The forecast is subject to significant uncertainties due to the Hospital Reform Adjustment Act (KHAG) and the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-BStabG), which aim to improve quality and efficiency but are expected to put hospitals under greater financial pressure in the short term. The company also faces ongoing global crises and economic impacts that may lead to higher prices, supply bottlenecks, and market volatility. The Quarterly Statement for Q3 2026 is available on the Internet. RHON-KLINIKUM AG operates five highly specialized maximum- and intermediate-care facilities and employs over 19,100 people, treating approximately 938,000 patients annually. More information about the company is available at www.rhoen-klinikum-ag.com.
